-
Phase 1
-
-
18+Age Range
-
Active, Not Recruiting
Active, Not Recruiting
Trial of BMS-986012 in Combination With Platinum and Etoposide
The purpose of this this study is to administer BMS-986012 in Combination with Platinum and Etoposide as First-line Therapy in Extensive Small Cell Lung Cancer.
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - Male and Females 18 years of age or older - Pulmonary SCLC documented by histology or cytology - Extensive disease (Stage IV) SCLC - Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 Exclusion Criteria: - Prior systemic therapy for lung cancer - Symptomatic brain metastases - Grade 2 peripheral neuropathy - Active or chronic infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV - Other active malignancies or prior malignancy within 2 years Other protocol defined inclusion/exclusion criteria could apply
Active Comparator: Active Comparator Arm 3B
Experimental: Experimental Arm 1
Experimental: Experimental Arm 2
Experimental: Experimental Arm 3A